| Literature DB >> 31031660 |
Dimitri Hefter1,2, Cristina E Topor1, Peter Gass1, Dusan Hirjak1.
Abstract
Background: Catatonic phenomena such as stupor, mutism, stereotypy, echolalia, echopraxia, affective flattening, psychomotor deficits, and social withdrawal are characteristic symptoms of both schizophrenia and autism spectrum disorders (ASD), suggesting overlapping pathophysiological similarities such as altered glutamatergic and dopaminergic synaptic transmission and common genetic mutations. In daily clinical practice, ASD can be masked by manifest catatonic or psychotic symptoms and represent a diagnostic challenge, especially in patients with unknown or empty medical history. Unclear diagnosis is one of the main factors for delayed treatment. However, we are still missing diagnostic recommendations when dealing with ASD patients suffering from catatonic syndrome. Case presentation: A 31-year-old male patient without history of psychiatric disease presented with a severe catatonic syndrome and was admitted to our closed psychiatric ward. After the treatment with high-dose lorazepam and intramuscular olanzapine, catatonic symptoms largely remitted, but autistic traits persisted. Following a detailed anamnesis and a thorough neuropsychological testing, we diagnosed the patient with high-functioning autism and catatonic schizophrenia. The patient was discharged in a remitted state with long-acting injectable olanzapine.Entities:
Keywords: acute psychiatry; autism; catatonia; coercive treatment; diagnostic challenge; schizophrenia
Year: 2019 PMID: 31031660 PMCID: PMC6473553 DOI: 10.3389/fpsyt.2019.00224
Source DB: PubMed Journal: Front Psychiatry ISSN: 1664-0640 Impact factor: 4.157
Figure 1Clinical time course. (A) Patient’s MRI, sample horizontal planes (3 mm) at the height of ventricles, taken on a 3-Tesla scanner. Upper image: Turbo-Inversion Recovery-Magnitude (TIRM) sequence with fluid suppression; bottom: T2 blade sequence. (B) The time course of NCRS and PANSS scores is depicted on the upper and the lower subplots, respectively. The patient was independently scored at five time points throughout treatment and follow-up (as marked on the upper x axis) by the two first authors of the paper; then, the mean score was calculated. Big cyan-filled circles represent the total scores; small red, blue, and green dots represent the subdomains of the tests. Major therapeutic and diagnostic milestones are marked on the bottom x axis. Treatment 1–4: 1, enforced medication with lorazepam and isotonic infusions; 2, enforced medication with lorazepam and oral olanzapine 10–15 mg daily; 3, enforced medication with intramuscular olanzapine 300 mg biweekly; 4, voluntary medication with intramuscular olanzapine 300 mg biweekly.
Neuropsychological measures.
| 1.1 IST-2000R IQ test | |
|---|---|
|
|
|
| Verbal intelligence | 67 |
| Numerical intelligence | 84 |
| Figurative–spatial intelligence | 72 |
| Mean | 74 |
| 1.2 MBAS | |
|
|
|
| A (Theory of mind, social interaction) | 35 (38) |
| B (Divided attention, facial expression, gestures) | 32 (21) |
| C (Stereotypes and situation-inadequate behavior) | 24 (20) |
| D (Peculiar speech patterns, interests, movements) | 23 (16) |
| Total | 114 (103) |
| Retardation of speech development | Yes |
| 1.3 SCID-II | |
|
|
|
| Avoidant | 6 (4) |
| Obsessive–compulsive | 5 (4) |
| Schizoid | 4 (4) |
| Antisocial | 3 (3) |
| 1.4 Facial emotion recognition | |
|
|
|
| Fear | 87 (2.18) |
| Anger | 47 (2.64) |
| Happiness | 100 (2.21) |
| Neutral | 87 (3.51) |
| Total mean | 80 (2.59) |
| 1.5 The Autism Diagnostic Observation Schedule | Score (cutoff) |
| Total | 17 (7) |